Background: Chronic diarrhoea affects 5–10% of the adult population. Histologic lesions of possible diagnostic significance are found under normal colonoscopy in approximately 30% of patients affected by chronic diarrhoea. Mastocytic enterocolitis is characterized by an increase in the number of mucosal mast cells (MC) in the gut of patients with chronic intractable diarrhoea, detected by immunohistochemical staining, responding to mast-cell targeted drugs. The question arises whether to search for MC infiltration in specific subsets of patients as a matter of routine clinical practice. Summary: A systematic electronic search of the English literature up to December 2017 was performed, using Medline, EMBASE, Web of Science, Scopus, and the Cochrane Library. This revealed 9 studies reporting an increased number of MC in the gut mucosa of patients with chronic diarrhoea. No consensus was found, however, on the actual cutoff point, the overlap in range between patients and controls being too great to be of clinical significance. The available evidence does not therefore justify the routine evaluation of MC count. Key Messages: More studies are needed to better define MC count and the significance of MC degranulation in normal and pathological settings. Until these become available, the search for MC infiltration in specific subsets of patients should be restricted to research settings.

1.
Tangri V, Chande N: Microscopic colitis: an update. J Clin Gastroenterol 2009; 43: 293–296.
2.
da Silva JG, De Brito T, Cintra Damião AO, Laudanna AA, Sipahi AM: Histologic study of colonic mucosa in patients with chronic diarrhea and normal colonoscopic findings. J Clin Gastroenterol 2006; 40: 44–48.
3.
Bohr J, Wickbom A, Hegedus A, Nyhlin N, Hultgren-Hörnquist E, Tysk C: Diagnosis and management of microscopic colitis: current perspectives. Clin Exp Gastroenterol 2014; 7: 273–284.
4.
Langner C, Aust D, Ensari A, Villanacci V, Becheanu G, Miehlke S, Geboes K, Münch A; Working Group of Digestive Diseases of the European Society of Pathology (ESP) and the European Microscopic Colitis Group (EMCG): Histology of microscopic colitis-review with a practical approach for pathologists. Histopathology 2015; 66: 613–626.
5.
Münch A, Aust D, Bohr J, Bonderup O, Fernández Bañares F, Hjortswang H, Madisch A, Munck LK, Ström M, Tysk C, Miehlke S: Microscopic Colitis: current status, present and future challenges: Statements of the European Microscopic Colitis Group. J Crohns Colitis 2012; 6: 932–945.
6.
Ribatti D: The development of human mast cells. An historical reappraisal. Exp Cell Res 2016; 342: 210–215.
7.
Galli SJ, Grimbaldeston M, Tsai M: Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008; 8: 478–486.
8.
Reber LL, Sibilano R, Mukai K, Galli SJ. Potential effector and immunoregulatory functions of mast cells in mucosal immunity. Mucosal Immunol 2015; 8: 444–463.
9.
Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M: Mast cells as “tunable” effector and immunoregulatory cells: recent advances Annu Rev Immunol 2005; 23: 749–786.
10.
Rivera J, Fierro NA, Olivera A, Suzuki R: New insights on mast cell activation via the high affinity receptor for IgE. Adv Immunol 2008; 98: 85–120.
11.
Boyce JA: Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev 2007; 217: 168–185.
12.
Skokos D, Botros HG, Demeure C, Morin J, Peronet R, Birkenmeier G, Boudaly S, Mécheri S: Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 2003; 170: 3037–3045.
13.
Ramsay DB, Stephen S, Borum M, Voltaggio L, Doman DB: Mast cells in gastrointestinal disease. Gastroenterol Hepatol (N Y) 2010; 6: 772–777.
14.
Krystel-Whittemore M, Dileepan KN, Wood JG: Mast Cell: A Multi-Functional Master Cell. Front Immunol 2016; 6: 620.
15.
Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB: Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A 1986; 83: 4464–4468.
16.
Bischoff SC, Wedemeyer J, Herrmann A, Meier PN, Trautwein C, Cetin Y, Maschek H, Stolte M, Gebel M, Manns MP: Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996; 28: 1–13.
17.
Bischoff SC: Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol 2007; 7: 93–104.
18.
Stead RH, Dixon MF, Bramwell NH, Riddell RH, Bienenstock J: Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology 1989; 97: 575–585.
19.
Jakate S, Demeo M, John R, Tobin M, Keshavarzian A: Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea. Arch Pathol Lab Med 2006; 130: 362–367.
20.
Akhavein MA, Patel NR, Muniyappa PK, Glover SC: Allergic mastocytic gastroenteritis and colitis: an unexplained etiology In chronic abdominal pain and gastrointestinal dysmotility. Gastroenterol Res Pract 2012; 2012: 950582.
21.
Shukla SA, Veerappan R, Whittimore JS, Ellen Miller L, Youngberg GA: Mast cell ultrastructure and staining in tissue. Methods Mol Biol 2006; 315: 63–76.
22.
Valent P, Cerny-Reiterer S, Herrmann H, Mirkina I, George TI, Sotlar K, Sperr WR, Horny HP: Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol 2010; 23: 369–378.
23.
Hiatt RB, Katz L: Mast cells in inflammatory conditions of the gastrointestinal tract. Am J Gastroenterol 1962 May; 37: 541–545.
24.
He SH: Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 2004; 10: 309–318.
25.
Dvorak AM, Monahan RA, Osage JE, Dickersin GR: Crohn’s disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Hum Pathol 1980; 11: 606–619.
26.
Nolte H, Spjeldnaes N, Kruse A, Windelborg B: Histamine release from gut mast cells from patients with inflammatory bowel diseases. Gut 1990; 31: 791–794.
27.
Nishida Y, Murase K, Isomoto H, Furusu H, Mizuta Y, Riddell RH, Kohno S: Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease. Hepatogastroenterology 2002; 49: 678–682.
28.
Gelbmann CM, Mestermann S, Gross V, Kollinger M, Scholmerich J, Falk W: Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 1999; 45: 210–217.
29.
Raithel M, Matek M, Baenkler HW, Jorde W, Hahn EG: Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. Int Arch Allergy Immunol 1995; 108: 127–133.
30.
Knutson L, Ahrenstedt O, Odlind B, Hallgren R: The jejunal secretion of histamine is increased in active Crohn’s disease. Gastroenterology 1990; 98: 849–854.
31.
Raithel M, Winterkamp S, Pacurar A, Ulrich P, Hochberger J, Hahn EG: Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 2001; 36: 174–179.
32.
Mekori YA, Metcalfe DD: Mast cell-T cell interactions. J Allergy Clin Immunol 1999; 104: 517–523.
33.
Binder V, Elsborg L, Greibe J, Hendriksen C, Høj L, Jensen KB, Kristensen E, Madsen JR, Marner B, Riis P, Willumsen L: Disodium cromoglycate in the treatment of ulcerative colitis and Crohn’s disease. Gut 1981; 22: 55–60.
34.
Williams SE, Grundman MJ, Baker RD, Turnberg LA: A controlled trial of disodium cromoglycate in the treatment of Crohn’s disease. Digestion 1980; 20: 395–398.
35.
Buckell NA, Gould SR, Day DW, Lennard-Jones JE, Edwards AM: Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis. Gut 1978; 19: 1140–1143.
36.
Walker MM, Talley NJ, Prabhakar M, Pennaneac’h CJ, Aro P, Ronkainen J, Storskrubb T, Harmsen WS, Zinsmeister AR, Agreus L: Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29: 765–773.
37.
Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martínez C, Casellas F, Saperas E, Malagelada JR: Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203–209.
38.
Weston AP, Biddle WL, Bhatia PS, Miner PB Jr: Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993; 38: 1590–1595.
39.
O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O’Morain CA: Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449–457.
40.
Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC: Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006; 21(1 pt 1): 71–78.
41.
Bednarska O, Walter SA, Casado-Bedmar M, Ström M, Salvo-Romero E, Vicario M, Mayer EA, Keita ÅV: Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome. Gastroenterology 2017; 153: 948–960.
42.
Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693–702.
43.
Lunardi C, Bambara LM, Biasi D, Cortina P, Peroli P, Nicolis F, Favari F, Pacor ML: Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Clin Exp Allergy 1991; 21: 569–572.
44.
Bolin TD: Use of oral sodium cromoglycate in persistent diarrhoea. Gut 1980; 21: 848–850.
45.
Stefanini GF, Saggioro A, Alvisi V, Angelini G, Capurso L, di Lorenzo G, Dobrilla G, Dodero M, Galimberti M, Gasbarrini G, et al: Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol 1995; 30: 535–541.
46.
Ebrahimi Daryani N, Hashemian F, Afkham M, Habibollahi P, Keramati MR, Fereshtehnejad SM, Bashashati M: Mast cell stabilizers as a potential treatment for Irritable bowel syndrome: a randomized placebo-controlled clinical trial. DARU 2009; 17: 72–78.
47.
Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE: The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59: 1213–1221.
48.
Yen EF, Pardi DS: Review article: microscopic colitis – lymphocytic, collagenous and “mast cell” colitis. Aliment Pharmacol Ther 2011; 34: 21–32.
49.
Schwab D, Raithel M, Hahn EG: Evidence for mast cell activation in collagenous colitis. Inflamm Res 1998; 47(suppl 1): S64–S65.
50.
da Silveira AB, Adad SJ, Correa-Oliveira R, Furness JB, D’Avila Reis D: Morphometric study of eosinophils, mast cells, macrophages and fibrosis in the colon of chronic chagasic patients with and without megacolon. Parasitology 2007; 134(pt 6): 789–796.
51.
Hermanowicz A, Debek W, Dzienis-Koronkiewicz E, Chyczewski L: Topography and morphometry of intestinal mast cells in children with Hirschsprung’s disease. Folia Histochem Cytobiol 2008; 46: 65–68.
52.
Freitas MA, Segatto N, Tischler N, de Oliveira EC, Brehmer A, da Silveira AB: Relation between mast cells concentration and serotonin expression in chagasic megacolon development. Parasite Immunol 2017; 39.
53.
Blirando K, Milliat F, Martelly I, Sabourin JC, Benderitter M, François A: Mast cells are an essential component of human radiation proctitis and contribute to experimental colorectal damage in mice. Am J Pathol 2011; 178: 640–651.
54.
Lu F, Huang S: The Roles of Mast Cells in Parasitic Protozoan Infections. Front Immunol 2017; 8: 363.
55.
Suranyi Y, Freier S, Faber J, Dollberg L: Intestinal mast cells in different stages of celiac disease. Isr J Med Sci 1986; 22: 370–375.
56.
Bassotti G, Villanacci V, Nascimbeni R, Cadei M, Manenti S, Sabatino G, Maurer CA, Cathomas G, Salerni B: Colonic mast cells in controls and slow transit constipation patients. Aliment Pharmacol Ther 2011; 34: 92–99.
57.
Bassotti G, Villanacci V, Nascimbeni R, Antonelli E, Cadei M, Manenti S, Lorenzi L, Titi A, Salerni B. The role of colonic mast cells and myenteric plexitis in patients with diverticular disease. Int J Colorectal Dis 2013; 28: 267–272.
58.
Ogilvie-McDaniel C, Blaiss M, Osborn FD, Carpenter J: Mastocytic enterocolitis: a newly described mast cell entity. Ann Allergy Asthma Immunol 2008; 101: 645–646.
59.
Thonhofer R, Siegel C, Trummer M, Langner C: Mastocytic enterocolitis as a rare cause of chronic diarrhea in a patient with rheumatoid arthritis. Wien Klin Wochenschr 2011; 123: 297–298.
60.
Seo H, Park SH, Byeon JS, Woo CG, Hong SM, Chang K, So H, Kwak M, Kim WS, Lee JM, Yang DH, Kim KJ, Ye BD, Myung SJ, Yang SK: Chronic intractable diarrhea caused by gastrointestinal mastocytosis. Intest Res 2016; 14: 280–284.
61.
Capannolo A, Viscido A, Sollima L, Marinucci A, Coletti G, Pasetti A, Frieri G, Bassotti G, Villanacci V, Latella G: Mastocytic enterocolitis: Increase of mast cells in the gastrointestinal tract of patients with chronic diarrhea. Gastroenterol Hepatol 2017; 40: 467–470.
62.
Zare-Mirzaie A, Lotfi M, Sadeghipour A, Haghi-Ashtiani MT: Analysis of colonic mucosa mast cell count in patients with chronic diarrhea. Saudi J Gastroenterol 2012; 18: 322–326.
63.
Sethi A, Jain D, Roland BC, Kinzel J, Gibson J, Schrader R, Hanson JA: Performing colonic mast cell counts in patients with chronic diarrhea of unknown etiology has limited diagnostic use. Arch Pathol Lab Med 2015; 139: 225–232.
64.
Doyle LA, Sepehr GJ, Hamilton MJ, Akin C, Castells MC, Hornick JL. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol 2014; 38: 832–843.
65.
Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC: Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006; 21: 71–78.
66.
Schaeffer DF, Kirsch R, Riddell RH: Mast cells and intestinal motility disorders (mastocytic enteritis/colitis). Dig Dis Sci 2012; 57: 1118–1121.
67.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC: Functional bowel disorders. Gastroenterology 2006; 130: 1480–1491.
68.
Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL: Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci 2000; 45: 1166–1171.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.